Fig 1.
Trial profile for the entire cohort (both sites combined).
SP = sulfadoxine-pyrimethamine. CD = chlorproguanil-dapsone. MQ = mefloquine. HET = heterozygous. HH = homo-/hemizygous.
Table 1.
Demographic and clinical data at enrollment among G6PD genotyped children with successful G6PD genotyping results.
Table 2.
Adjusted treatment effects on changes in hemoglobin 7, 14, and 28 days after an IPTi dose.
Table 3.
Adjusted genotype effects on hemolysis 7, 14, and 28 days after an IPTi dose among treated infants.
Table 4.
Adjusted treatment effects on changes in hemoglobin 7, 14, and 28 days after an IPTi dose, by G6PD genotype.